Most of these phosphoproteins were involved in alterations of the BCR signaling, as well as some routes of B lymphocyte activation, which are highly correlated with the CLL therapeutic algorithm and disease progression. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.